Broad patterns of use of the gene signature panel Oncotype DX DCIS and its large-scale impact on postoperative administration of radiation therapy in women with ductal carcinoma in situ of the breast remain unclear. This study sought to evaluate the patterns of use of this gene signature panel in women with ductal carcinoma in situ and the impact of these tools on postoperative radiation therapy administration.
The National Cancer Database was queried for women with ductal carcinoma in situ treated with breast-conserving therapy who had information regarding whether a gene signature panel was performed between 2010 and 2015. Demographic characteristics, the characteristics of their ductal carcinoma in situ, and whether they received postoperative radiation therapy were compared among patients who did have a gene signature panel performed and those who did not. Patterns of radiation therapy administration were also evaluated based on the recurrence risk score by the gene signature panel.
Gene signature panel use increased over time, with a sharp increase in utilization occurring in 2015 (8.0% in 2015 vs 4.4% in 2014, P < .001). Patients with estrogen receptor–positive ductal carcinoma in situ were somewhat more likely to have a gene signature panel ordered (3.9% estrogen receptor positive vs 1.7% estrogen receptor negative, P < .001), as were patients with lower-grade ductal carcinoma in situ (4.5% grade I/II vs 3.1% grade III, P < .001). Gene signature panel utilization was associated with a decrease in the administration of postoperative radiation therapy (48.6% gene signature panel vs 83.4% no gene signature panel, P < .001). Among patients in whom a gene signature panel was performed, postoperative radiation therapy was administered in 81.9%, 72.0%, and 35.9% of patients with high-, intermediate-, and low-recurrence scores, respectively.
Gene signature panel use in patients with ductal carcinoma in situ has increased over time and is more commonly used in women with lower-risk, clinicopathologic features to determine the magnitude of benefit afforded by radiation therapy. Gene signature panel use is associated with decreased rates of postoperative radiation therapy administration, particularly among patients with scores suggesting a low rate of recurrence.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Surgery
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Clinical utility of multigene profiling assays in early-stage breast cancer.Curr Oncol. 2017; 24: e403-e422
- The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2− early breast cancer.Br J Cancer. 2014; 111: 837-842
- Multigene prognostic tests in breast cancer: Past, present, future.Breast Cancer Res. 2015; 17: 11
- The era of multigene panels comes? The clinical utility of Oncotype DX and Mammaprint.World J Oncol. 2017; 8: 34-40
- Multigene signature panels and breast cancer therapy: Patterns of use and impact on clinical decision making.J Am Coll Surg. 2018; 226: 406-412.e401
- 21-gene recurrence score assay as a predictor of adjuvant chemotherapy administration for early-stage breast cancer: An analysis of use, therapeutic implications, and disparity profile.J Clin Oncol. 2016; 34: 1995-2002
- Prospective study of the effect of the 21-gene assay on adjuvant clinical decision-making in Japanese women with estrogen receptor-positive, node-negative, and node-positive breast cancer.Clin Breast Cancer. 2014; 14: 191-197
- A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.J Natl Cancer Inst. 2013; 105: 701-710
- A population-based validation study of the DCIS score predicting recurrence risk in individuals treated by breast-conserving surgery alone.Breast Cancer Res Treat. 2015; 152: 389-398
- The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS score result.J Surg Oncol. 2015; 111: 935-940
- NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS).NIH Consens State Sci Statements. 2009; 26: 1-27
- Clinical utility of the 12-gene DCIS score assay: Impact on radiotherapy recommendations for patients with ductal carcinoma in situ.Ann Surg Oncol. 2017; 24: 660-668
- The LORIS trial: Addressing overtreatment of ductal carcinoma in situ.Clin Oncol. 2015; 27: 6-8
- Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ.J Natl Cancer Inst. 2016; 109
- Disparities in compliance with the Oncotype DX breast cancer test in the United States: A National Cancer Data Base assessment.Am J Surg. 2018; 215: 686-692
- Patient experiences and clinician views on the role of radiation therapy for ductal carcinoma in situ.Int J Radiat Oncol Biol Phys. 2018; 100: 1237-1245
- Cost effectiveness of the oncotype DX DCIS score for guiding treatment of patients with ductal carcinoma in situ.J Clin Oncol. 2016; 34: 3963-3968
- Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.J Natl Cancer Inst. 2011; 103: 478-488
- Breast cancer screening and diagnosis, version 3.2018.2018Accessed April 19, 2019)
- Best practices for multidisciplinary integration of a DCIS genomic assay into clinical practice.J Surg Oncol. 2017; 116: 1016-1020
- Multigene expression assay and benefit of radiotherapy after breast conservation in ductal carcinoma in situ.J Natl Cancer Inst. 2017; 109
- Management of low-risk DCIS (LORD).Clinicaltrials.gov identifier: NCT02492607. Accessed March 27, 2019)
- Comparison of Operative to Monitoring and Endocrine Therapy (COMET) trial for low risk DCIS (COMET).Clinicaltrials.gov identifier: NCT02926911. Accessed March 27, 2019)
Published online: July 20, 2019
Accepted: April 16, 2019
© 2019 Elsevier Inc. All rights reserved.